Introduction: Therapeutic options for mycosis fungoides and Sézary syndrome include a variety of immunomodulatory, epigenetic, and cytotoxic options; however, none has been demonstrated to be efficacious for all patients, or to deliver deep and durable responses to the majority of patients. In this review, we examine the monoclonal antibody, IPH4102, a novel agent for the treatment of cutaneous T-cell lymphoma.
Areas covered: In this review, we examine data demonstrating the tissue specificity of KIR3DL2 receptor, which is highly expressed on the malignant cells in cutaneous T-cell lymphoma, including mycosis fungoides and Sézary syndrome. This specificity has led to the development of the agent IPH4102. Preclinical data showing efficacy of IPH4102 in vivo are outlined, as well as the results from Phase I clinical trials, which suggest that the agent is both efficacious and well-tolerated. Larger scale clinical trials are to follow.
Expert Opinion: We examine the putative benefit of IPH4102 in comparison to established agents already in the clinic, highlighting its efficacy and relative safety. We also examine possible directions that may better define the role of IPH4102 in the treatment of T-cell lymphoma in the future. 相似文献
目的探究服用抗精神药物与引起精神疾病患者代谢综合征以及认知功能的关系。方法选取2015年6月—2017年6月在上海市浦东新区南汇精神卫生中心进行治疗的精神分裂症患者80例,并按照患者的择药意见将其分为奥氮平组、喹硫平组和阿立哌唑组,分别给予患者奥氮平、喹硫平和阿立哌唑进行治疗。在治疗4、8和12周末从阳性和阴性症状量表(Positive and negative symptoms scale,PANSS)评分和社会功能缺陷量表(Social function defect scale,SDSS)评分方面对患者认知功能做出分析,并比较其治疗效果;在治疗4、8和12周末分别检查记录患者的体重、血糖、血脂和血压,分析研究代谢综合征的发生情况。结果三组患者在治疗后PANSS总分、阳性症状评分、阴性症状评分和一般病理症状评分方面均具有显著的改善,治疗前后相比具有显著差异,差异具有统计学意义(P0.05)。三组患者在治疗后SDSS较治疗前均有明显的减少,与治疗前比较,差异具有统计学意义(P0.05);从三组患者治疗效果的结果中可以看出,在经过三种药物治疗之后,患者均具有较大的改善,其中,奥氮平组的总有效率达92.59%,喹硫平组总有效率达96.30%,阿立哌唑组的总有效率达96.15%,三组相比没有显著差异。从三组患者的代谢综合征发病情况来看,奥氮平组具有较高的发病率,患病率37.03%。喹硫平组代谢综合征的患病率相对较低,患病率18.52%。阿立哌唑组患者发生代谢综合征的情况较好,仅有11.54%的发生率。与奥氮平组相比,具有显著的差异,差异具有统计学意义(P0.05)。结论奥氮平、喹硫平及阿立哌唑对精神患者均具有较好的治疗效果,均能够有效的改善患者的社会认知功能;喹硫平及阿立哌唑在具有较好治疗效果的同时对患者的不良影响较小,具有较低的代谢综合征发病率,值得推广使用。 相似文献
Intestinal failure–associated liver disease (IFALD) occurs commonly in intestinal transplant (ITx) candidates receiving parenteral nutrition (PN). The aim of this study is to establish the prevalence and risk factors for advanced liver fibrosis in adults at the time of ITx.
Methods
Retrospective chart review of all ITx was performed in adults between January 2000 and May 2014. Advanced liver fibrosis was defined as stage 3 or stage 4 fibrosis.
Results
Fifty‐three patients met the inclusion criteria. The mean age was 50.6 ± 10.9 years, and the majority were female (60.4%) and Caucasian (67.9%). The mean body mass index was 21.7 ± 3.8 kg/m2 and the median duration of PN was 402 (interquartile range: 529) days. Advanced liver fibrosis at the time of ITx was found in 13 patients (24.5%). The multivariate analysis revealed that female gender and white race were significant predictors of advanced liver fibrosis. A total bilirubin >3.0 mg/dL for > a month prior to ITx was associated with an odds ratio of 8.9 for advanced fibrosis at the time of ITx but did not reach statistical significance (P = 0.055).
Conclusion
Close to one‐quarter of the ITx recipients had advanced liver fibrosis. In the current era of improved PN management, our data suggests that previously reported risk factors for IFALD, such as extreme short gut syndrome and PN duration, may have a lesser impact on development of liver fibrosis. A prolonged duration of bilirubin elevation may be associated with advanced liver fibrosis in patients with IFALD, but this requires validation in a larger cohort. 相似文献